scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Company profile
Ticker
SCYX
Exchange
Website
CEO
Marco Taglietti
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
SCYX stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
SCYNEXIS Reports Full Year 2023 Financial Results
28 Mar 24
8-K
A dynamic force in the fight against infectious disease January 2024
5 Jan 24
8-K
Entry into a Material Definitive Agreement
2 Jan 24
424B5
Prospectus supplement for primary offering
28 Nov 23
424B5
Prospectus supplement for primary offering
28 Nov 23
EFFECT
Notice of effectiveness
28 Nov 23
EFFECT
Notice of effectiveness
28 Nov 23
CORRESP
Correspondence with SEC
21 Nov 23
Latest ownership filings
4
Scott Sukenick
16 Feb 24
SC 13G/A
CAXTON CORP
13 Feb 24
SC 13G/A
Avidity Partners Management LP
13 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
144
Notice of proposed sale of securities
5 Feb 24
4
Gonzalez David Angulo
30 Jan 24
4
ivor Macleod
30 Jan 24
4
Scott Sukenick
30 Jan 24
SC 13G/A
FEDERATED HERMES, INC.
18 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 44.62 mm | 44.62 mm | 44.62 mm | 44.62 mm | 44.62 mm | 44.62 mm |
Cash burn (monthly) | 4.63 mm | 2.02 mm | 3.37 mm | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 31.00 mm | 13.52 mm | 22.54 mm | n/a | n/a | n/a |
Cash remaining | 13.61 mm | 31.10 mm | 22.07 mm | n/a | n/a | n/a |
Runway (months of cash) | 2.9 | 15.4 | 6.6 | n/a | n/a | n/a |
Institutional ownership, Q3 2023
51.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 63 |
Opened positions | 15 |
Closed positions | 10 |
Increased positions | 12 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 36.94 bn |
Total shares | 19.45 mm |
Total puts | 27.50 k |
Total calls | 65.70 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
FHI Federated Hermes Inc - Ordinary Shares | 4.80 mm | $10.95 bn |
Stonepine Capital Management | 2.85 mm | $6.50 bn |
Kingdon Capital Management, L.L.C. | 1.88 mm | $4.28 bn |
Flynn James E | 1.50 mm | $0.00 |
Vanguard | 1.49 mm | $3.39 bn |
Avidity Partners Management | 1.32 mm | $3.01 bn |
Hirschman Orin | 1.16 mm | $2.32 mm |
Decheng Capital Management III | 555.56 k | $1.27 bn |
D.a. Davidson & Co. | 486.33 k | $1.11 bn |
BLK Blackrock | 430.91 k | $982.47 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 24 | Scott Sukenick | Common Stock | Payment of exercise | Dispose F | No | No | 1.63 | 15,179 | 24.74 k | 336,195 |
26 Jan 24 | Scott Sukenick | Common Stock | Grant | Acquire A | No | No | 0 | 143,675 | 0.00 | 351,374 |
26 Jan 24 | Scott Sukenick | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.86 | 215,515 | 400.86 k | 215,515 |
26 Jan 24 | ivor Macleod | Common Stock | Grant | Acquire A | No | No | 0 | 143,675 | 0.00 | 160,185 |
26 Jan 24 | ivor Macleod | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.86 | 215,515 | 400.86 k | 215,515 |
26 Jan 24 | Gonzalez David Angulo | Common Stock | Grant | Acquire A | No | No | 0 | 290,590 | 0.00 | 479,871 |
26 Jan 24 | Gonzalez David Angulo | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.86 | 431,030 | 801.72 k | 431,030 |
15 Jun 23 | Macdonald Guy | Common Stock | Grant | Acquire A | No | No | 0 | 10,000 | 0.00 | 32,000 |
Press releases
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
9 Apr 24
SCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology Conference
30 Jan 24
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
29 Jan 24